• search
Antibody Drug Conjugate Services Antibody Drug Conjugate Services

Antibody Drug Conjugate Services

Aurigene Pharmaceutical Services provides unique advantage of having a linker-payload chemistry, antibody discovery and engineering, conjugation and characterization services under one roof. Our team has experience in working with versatile novel and standard ADC technology platforms.

Antibody, linker-payload, conjugation and analytics – we provide a one-stop solution for ADC discovery and development.     

We understand the dynamic nature of the current ADC technology landscape and the complexities associated with it. Our team is well versed with a wide range of ADC technologies and is capable of adapting new technologies to support our client needs. We also provide expertise to develop novel liker technologies and cytotoxic payload optimization.     

We offer a wide range of ADC services, and our team is competent at adapting new technologies to meet client requirements.

Speak to our experts

Linker Technologies

We offer services for designing and synthesizing ADC linkers and linker-drug conjugates. Based on the drug release mechanism, we design & synthesize different ADC linkers: Cleavable and non-cleavable linkers, self-immolation tracer-free linkers, and peptide linkers.

Conjugation Technologies

Our team carries out ADC conjugation services to accelerate the production of ADC constructs with quality attributes.     
Amine (Lys) conjugation, thiol (Cys) conjugation, site-specific conjugation, enzymatic conjugation, glycoconjugation and click chemistry.


According to clients’ requirements, we optimize payloads such as cytotoxic, non-cytotoxic, and biological payloads. Our team handles a wide range of cytotoxic payloads, including:

  • Auristatins (MMAE and MMAF)
  • Tubulysin
  • PBD Dimer
  • Maytansinoids (DM-1, DMO4)
  • Duocarmycin
  • Exatecans

ADC Discovery (Therapeutics and Tools or Reagents) and Development

Our ADC discovery programs are customized as per the target biology and desired mechanism of action. Specific screening strategies are designed and employed at a stage as early as antibody generation. Some of the early stage activities include screening and design of mAbs for internalization (or lack of it), effector function, off-site localization and half-life.     

Rapid and comprehensive scouting of the linker-payload technology space can be plugged-in to identify the most desirable combinations of mAb, linker-payload and conjugation strategies. Stage appropriate in vitro screening and detailed evaluation of lead ADC molecules is carried out using customized assay platforms.     

We also provide in vivo therapeutic evaluation, PK, and rodent toxicology assessment support for ADC candidates with appropriate bioanalytical methods customized for each program. Conjugation and purification process development takes into account each component of the ADC molecule. Quality, scalability, safety and cost-effectiveness concerns are addressed at each stage of process development.

ADC Analysis

A biomolecule is complex as an ADC and demands analytical assessment to ensure safety and quality. Routinely determined attributes during ADC analysis are

  • DAR average
  • Free-drug
  • Conjugation site
  • Aggregation
  • Fragmentation
  • Endotoxin
  • Antigen binding affinity
  • Plasma stability
  • In vitro potency

Why Aurigene Pharmaceutical Services?

Site-specific conjugation technology

In-house linker library and Payload

Collaborative and solution driven

Analytical assessment to ensure safety and quality

Various commercial and customized linkers

Virtual Tour

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...

Read More

Systematic formulation design - shorten development cost & time

Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...

Read More

An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives


A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.